KONEXElectrical Equipment337840

UXN

₩6,000▲ 0.17%2026-11-18 close
Market Cap
₩29.9B
Turnover
₩8,390,070
Volume
1.4K
Shares out.
5M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Commercializing a non-enzymatic CGM under capital erosion

UXN's non-enzymatic platinum CGM is advancing in clinical and patent terms, but thin revenue and negative equity leave balance-sheet repair as the central variable.

  1. 1

    On a separate-basis 2025 reporting, revenue was KRW 153 million and operating loss was KRW 4,926 million, indicating the business has not yet reached product-driven revenue.

  2. 2

    According to company announcements, A1's MARD of 10.2% in exploratory trials was reported as comparable to the 9.2 to 10.7 range of Dexcom's G6.

  3. 3

    Total equity stood at KRW -1,108 million, and the conversion of SD Biosensor's convertible preferred shares into common stock has been cited as a factor that could improve the capital structure.

  4. 4

    Rights offering and convertible bond decisions in August 2026 were followed by an unfaithful-disclosure designation in September, leaving both capital-raising methods and disclosure management on record.

  5. 5

    The share price fell to KRW 4,870 on May 26, 2026, and traded at KRW 5,840 as of November 11, 2026.

02

Business structure

UXN is a medical device developer founded in May 2012 that develops a non-enzymatic continuous glucose monitor built on nanoporous platinum. Although the exchange classifies it under electrical equipment, its registered industry is other medical device manufacturing.

A technical analysis report published in September 2025 presented the enzyme-free structure as the basis for sensor chemical stability, mass-production suitability, and price competitiveness.

According to the same report, the company holds 23 registered patents and 70 pending applications, including core patents on the enzyme-free method. The product roadmap calls for commercializing A1, a health-screening device, in Korea first and then taking A2 to global markets.

A1 is positioned for continuous blood glucose measurement over several days after being worn on the day of a hospital checkup. According to company announcements, A1 recorded a MARD of 10.2% in exploratory trials.

The global CGM market is an oligopoly led by players such as Dexcom, and reports cite projections of growth from about USD 8.9 billion in 2023 to about USD 18.9 billion in 2028, a 16.5% compound annual rate.

Revenue comes mainly from prototype and sensor substrate sales and other income, with no full-scale product sales yet. According to 2025 reporting, SD Biosensor is the largest shareholder with a 22.16% stake, and CEO Park Se-jin is the second-largest with 12.50%.

03

Recent trends

The separate-basis 2025 financial statements were approved at the annual general meeting on March 31, 2026.

According to the same filing, total assets were KRW 10,539 million, revenue was KRW 153 million, total liabilities were KRW 11,647 million, operating loss was KRW 4,926 million, and net loss was KRW 3,025 million, with total equity at KRW -1,108 million. Loss per share was recorded at KRW 646.

On a 2024 settlement basis, revenue was reported at about KRW 500 million and operating loss at about KRW 5.8 billion, so 2025 revenue fell sharply from that level. Shares outstanding at year-end 2024 comprised 3,725,041 common shares and 1,392,533 preferred shares.

In October 2024, SD Biosensor applied for a payment order over KRW 19.62 billion tied to the third series of bonds with warrants, which moved the dispute into court proceedings.

Reports later said SD Biosensor would convert its 1,022,495 redeemable convertible preferred shares into common stock in full and the company would repay 75% of the bond principal and interest, settling the dispute.

On April 16, 2026, the company announced a US patent for core technology of its next-generation implantable CGM, and on September 23, 2026, it self-disclosed a patent for a continuous analyte measuring device.

In August 2026, a rights offering decision and a convertible bond issuance decision went through corrective filings, followed by an advance notice of an unfaithful-disclosure designation on September 2 and the designation itself on September 14, based on a reversal of disclosure. As of September 30, 2026, the share price was KRW 6,170, with a 52-week range of KRW 4,870 to KRW 11,980.

04

Outlook

In an IR letter dated May 21, 2026, the company stated that IRB approval for its clinical study had been completed. In April 2026, a press release on recognition by Korea's MFDS and a US patent announcement were issued, and patent disclosures continued after July.

The company has said it plans to move quickly toward product approval after the confirmatory trial of A1 and to launch it first for health-screening use in Korea. The KIND technical analysis report saw revenue upside if approvals and commercialization of A1 and A2 became visible.

The same report noted that delays could increase volatility in the growth path. On the financial side, the key question is whether the conversion of preferred shares into common stock, which moves debt into equity, leads to an actual reduction in capital impairment.

However, the rights offering and convertible bond decisions in August 2026 and the disclosure reversal in September remain alongside the possibility of further capital raising. According to reports, the company also plans to pursue a KOSDAQ transfer listing after A1 is commercialized.

Within a growing global CGM market and competition with leaders such as Dexcom, the results of A2's global entry are a medium-to-long-term variable.

05

Bull factors

Enzyme-free platinum technology and patent base

A KIND technical analysis report regards the nanoporous platinum enzyme-free method as core technology, noting that the absence of enzymes supports mass-production suitability and price competitiveness. A portfolio of 23 registered patents and 70 applications was presented as a factor that lowers patent dispute risk.

The company describes the April 2026 US patent and the September 2026 disclosure of a continuous analyte measuring device patent as evidence of a wider protection scope. However, patent counts alone do not guarantee commercial results.

Clinical metrics and regulatory progress

According to company announcements, A1's MARD of 10.2% in exploratory trials was reported as comparable to the 9.2 to 10.7 range of Dexcom's G6. A press release on MFDS recognition in April 2026 and the IRB approval notice of May 21, 2026 mark progress in clinical development.

The company has laid out a phased plan to launch A1 for domestic health-screening use first. Whether the clinical metrics translate into approval and actual sales remains open.

Signs of capital structure improvement

Reports said SD Biosensor would convert its 1,022,495 redeemable convertible preferred shares into common stock, shifting KRW 20 billion that had been carried as debt under IFRS into equity.

The BW early-redemption dispute was resolved with 75% of principal and interest repaid and the remaining 25% fixed at a set price with a three-year bar on early redemption claims, reducing legal uncertainty. This has been cited as a factor that could ease capital impairment. The actual size and timing of the accounting effect will appear in future periodic financial statements.

06

Bear factors

Limited revenue base and accumulated losses

On a separate-basis 2025 reporting, revenue was only KRW 153 million, with operating loss of KRW 4,926 million and net loss of KRW 3,025 million. Against a 2024 settlement-basis revenue of about KRW 500 million, the sharp drop in 2025 revenue shows the business remains before product launch.

Operating loss narrowed from about KRW 5.8 billion in 2024, but the reduction alone does not establish profitability improvement. Operating cash generation remains limited.

Capital impairment and debt burden

Total equity is negative at KRW -1,108 million, and total liabilities of KRW 11,647 million exceed total assets of KRW 10,539 million. Reporting from the first half of 2024 cited current liabilities due within one year of KRW 51.4 billion. Capital impairment can affect external financing terms. How much the preferred share conversion changes this structure will show in later financial statements.

Frequent capital raising and disclosure risk

A rights offering decision and a convertible bond issuance decision in August 2026 went through corrective filings, and a reversal of the bond issuance decision led to an advance notice of an unfaithful-disclosure designation on September 2, 2026 and the designation itself on September 14.

In October 2024, a payment order tied to the BW redemption was issued, adding to a history of disputes over capital raising. Frequent changes in disclosures reduce the predictability of financial information. Changes in capital-raising plans and disclosure controls may lead to further filings.

07

Risk factors

Macro and funding markets

As a KONEX-listed small cap with same-day trading value of about KRW 4.1 million, the stock is prone to large price reactions to changes in external funding markets and investor sentiment. The share price fell to KRW 4,870 on May 26, 2026 before recovering to KRW 5,840 by November 11, 2026, reflecting wide swings.

Changes in interest rates and growth-stock valuations affect the cost of raising capital. External financing capacity of a company with negative equity is sensitive to the macro backdrop.

The timing of the confirmatory trial results and product approval has not been fixed. The KIND technical analysis report noted that delays could increase volatility in the growth path.

If the exploratory trial results are not reproduced in the confirmatory study, the approval path and commercialization schedule could change. Overseas approval procedures differ by country, so the timing of A2's global entry could also slip.

In a global CGM market dominated by leaders such as Dexcom, new entrants must prove clinical performance, pricing, and distribution at the same time. The company's strategy targets domestic health-screening channels first, but how quickly those channels are secured remains open.

Falling sensor costs and subscription-style consumables models could intensify price competition. A2's global entry is a medium-to-long-term challenge.

08

Overall view

UXN is approaching commercialization on the strength of its non-enzymatic platinum CGM technology and progress in clinical and patent work.

Separate-basis 2025 figures of KRW 153 million in revenue, KRW 4,926 million in operating loss, and KRW -1,108 million in total equity show that business results have not yet reached the financial statements.

The conversion of SD Biosensor's preferred shares into common stock and the settlement of the BW dispute are positive factors that move part of the debt into equity.

On the other hand, rights offering and convertible bond decisions after August 2026 and the unfaithful-disclosure designation have drawn market attention to capital-raising methods and disclosure controls.

Exploratory trial metrics comparable to Dexcom's G6 show potential, but they are not verified results until the confirmatory trial and product approval are completed. Given its KONEX small-cap profile, trading volatility is also high.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 10 more articles and sources
  1. m.irgo.co.kr
  2. uxn.co.kr
  3. uxn.co.kr
  4. kind.krx.co.kr
  5. m.news.nate.com
  6. pharm.edaily.co.kr
  7. prestocknews.com
  8. comp.fnguide.com
  9. investing.com
  10. tradingview.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis